BGPT: Paper Review: ALK is a therapeutic target for lethal sepsis

Explore by Goal

Quick Answer Copied

Core claim: This Sci. Transl. Med study argues that ALK acts upstream of STING in monocytes/macrophages and that inhibiting the ALK–EGFR–AKT → TBK1/IRF3/NF-κB → IFN-β axis improves survival in lethal sepsis models in mice, with increased ALK/STING pathway activity reported in human sepsis PBMCs.

Primary source:

Long Answer

Paper Review (Visual + Skeptical): ALK is a therapeutic target for lethal sepsis

Sci. Transl. Med • Published Oct 18, 2017 • Primary DOI: 10.1126/scitranslmed.aan5689

1) Evidence ladder the authors use (what is shown vs inferred)

Shown (direct experimental measurements)

ALK inhibitors suppress STING-driven IFN-β release and IFN-β mRNA after STING ligand stimulation in macrophages/monocytes and across multiple cell systems.
Signaling readouts: reductions in p-TBK1, p-IRF3, and p-p65 (with unchanged total TBK1) upon ALK inhibition.
Genetics: ALK shRNA knockdown attenuates STING-driven IFN-β induction/release and phosphorylated signaling intermediates.
In vivo: ALK inhibition improves survival in a CLP polymicrobial sepsis model and an LPS endotoxemia model.
Human association: ALK/STING pathway transcripts and phosphorylated proteins in PBMCs appear elevated in the sepsis cohort vs healthy controls.

Inferred (mechanism that is not fully proven)

Mechanistic chain: proposed ALK→EGFR→AKT enabling STING activation; the paper reports increased ALK–EGFR interaction and phosphorylation changes consistent with this model.
Direct physical linking to STING: they report no direct interaction detected between ALK and known cytosolic STING pathway components (e.g., TBK1/cGAS/TRIF/S6), which implies an indirect routing via membrane RTK signaling; however, the exact intermediate(s) remain to be dissected.

2) Key quantitative in vivo result (survival)

The figure text in your provided paper excerpt includes a specific example survival comparison (STING+/+ vs STING−/− with vehicle vs LDK378).

3) Proposed signaling topology (compact map)

The following map summarizes the authors’ mechanistic proposal: ALK (cell-surface RTK) couples to EGFR and AKT to support STING-dependent TBK1/IRF3/NF-κB signaling and IFN-β output.

Skeptical note: The study reports no direct ALK binding to several cytosolic STING regulators (so this map reflects coupling inferred from pathway perturbation/RTK phosphorylation and ALK–EGFR interaction assays), not necessarily a single stoichiometric complex.

4) Critical appraisal (what could mislead, what remains unknown)

Major strengths

Convergent perturbations: both pharmacologic inhibition and genetic ALK knockdown suppress STING downstream phosphorylation and IFN-β output.
Multiple STING ligands and multiple immune cell systems are used for pathway readouts, which argues against ligand-specific coincidence.
In vivo efficacy with survival benefit in both CLP and LPS paradigms, and alignment with human PBMC pathway activation association.

Uncertainty / limitations (science reasons)

Pharmacology-to-biology gap: kinase inhibitors can have off-target effects; the paper mitigates this via ALK shRNA, but inhibitor selectivity at the doses used (and in vivo exposure) still determines interpretability.
Mechanism is plausible but not fully resolved: no direct ALK–STING component binding was detected; the exact intermediate(s) from membrane RTK signaling to TBK1 activation are not fully established.
Translational leap: human PBMC upregulation is associative; sepsis heterogeneity means pathway elevation may correlate with severity rather than causally drive lethal outcomes in all patients.
Biological context sensitivity: the paper discusses possible severity dependence (low-grade vs high-grade sepsis) and overlapping/distinct functions between ALK and STING; without more mechanistic dissection across disease stages, a single static model may overfit the tested paradigms.

5) Button: author reviews (direct links)

Run a self-contained science agent (iterative)

This will re-scan the provided full-text and perform additional structured checks (e.g., mapping claims to assay types, extracting all explicit numeric values present in your excerpt).

Feedback:

Updated: April 01, 2026